Pulmonx Corp (LUNG)

Currency in USD
2.22
-0.16(-6.72%)
Closed·
2.23+0.01(+0.45%)
·
LUNG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.162.37
52 wk Range
1.319.37
Key Statistics
Prev. Close
2.38
Open
2.34
Day's Range
2.16-2.37
52 wk Range
1.31-9.37
Volume
740.52K
Average Volume (3m)
2.63M
1-Year Change
-64.54%
Book Value / Share
1.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LUNG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.75
Upside
+159.01%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Pulmonx Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Pulmonx Corp Earnings Call Summary for Q2/2025

  • Q2 2025 revenue beat expectations at $23.9M, up 15% YoY; net loss of $0.38 per share, better than forecast
  • International revenue surged 32%, U.S. revenue grew 6%; stock price rose 1.94% post-earnings
  • 2025 revenue guidance revised to $90-92M, indicating 7-10% growth; focus on 'acquire, test, and treat' strategy
  • CEO highlights strong international performance, emphasizes long-term growth potential despite U.S. challenges
  • Risks include slower U.S. growth, capacity constraints, market competition, and potential regulatory delays
Last Updated: 30/07/2025, 22:58
Read Full Transcript

Compare LUNG to Peers and Sector

Metrics to compare
LUNG
Peers
Sector
Relationship
P/E Ratio
−1.6x−2.6x−0.6x
PEG Ratio
−0.390.170.00
Price/Book
1.5x3.9x2.6x
Price / LTM Sales
1.0x3.6x3.2x
Upside (Analyst Target)
102.7%45.4%41.8%
Fair Value Upside
Unlock28.6%5.1%Unlock

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.75
(+159.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy5.00+125.23%5.00Maintain13/11/2025
Lake Street Capital Markets
Buy4.00+80.18%8.00Maintain28/10/2025
Canaccord Genuity
Buy6.00+170.27%-Maintain28/10/2025
Wells Fargo
Hold3.00+35.14%6.00Maintain01/08/2025
Stifel
Buy5.00+125.23%16.00Maintain31/07/2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.34 / -0.42
Revenue / Forecast
21.50M / 20.78M
EPS Revisions
Last 90 days

People Also Watch

0.46
VSEE
+4.49%
2.430
CMND
-6.18%
2.190
PRLD
-3.10%
0.70
FTEL
+11.04%

FAQ

What Is the Pulmonx (LUNG) Share Price Today?

The live Pulmonx share price today is 2.22

What Stock Exchange Does Pulmonx (LUNG) Trade On?

Pulmonx is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Pulmonx?

The stock symbol (also called a 'ticker') for Pulmonx is "LUNG."

What Is the Current Pulmonx Market Cap?

As of today, Pulmonx market capitalisation is 92.39M.

What Is Pulmonx's (LUNG) Earnings Per Share (TTM)?

The Pulmonx EPS is currently -1.41 (Trailing Twelve Months).

When Is the Next Pulmonx Earnings Date?

Pulmonx's next earnings report will be released on 25 Feb 2026.

Is LUNG a Buy or Sell From a Technical Analyst Perspective?

Based on today's Pulmonx moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Pulmonx Stock Split?

Pulmonx has split 0 times. (See the LUNG stock split history page for full effective split date and price information.)

How Many Employees Does Pulmonx Have?

Pulmonx has 291 employees.

What is the current trading status of Pulmonx (LUNG)?

As of 24 Dec 2025, Pulmonx (LUNG) is trading at a price of 2.22, with a previous close of 2.38. The stock has fluctuated within a day range of 2.16 to 2.37, while its 52-week range spans from 1.31 to 9.37.

What Is Pulmonx (LUNG) Price Target According to Analysts?

The average 12-month price target for Pulmonx is USD5.75, with a high estimate of USD14 and a low estimate of USD2.5. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +159.01% Upside potential.

What Is the LUNG Premarket Price?

LUNG's last pre-market stock price is 2.39. The pre-market share volume is 200.00, and the stock has decreased by 0.01, or 0.42%.

What Is the LUNG After Hours Price?

LUNG's last after hours stock price is 2.23, the stock has decreased by 0.01, or 0.45%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.